P025 - ADHERENCE TO IMMUNOMODULATORY NUTRITIONAL THERAPY IN ONCOLOGY PATIENTS

P025

ADHERENCE TO IMMUNOMODULATORY NUTRITIONAL THERAPY IN ONCOLOGY PATIENTS

L. Matos^1,*, R. C. Bonadio¹, M. I. Braghiroli¹, P. Hoff¹, L. testa¹, S. Segatto², S. Gomes¹

¹oncology, Oncostar, ²oncology, ICESP, São Paulo, Brazil

Rationale: Nutritional support helps maintain or recover the nutritional status of oncology patients (pts_ undergoing treatment for various neoplasms. A key question is whether nutritional support can reduce treatment-related adverse events. Immunomodulatory substances, such as polyphenols, may reduce inflammation and oxidative damage, pathways involved in cytotoxic treatment-related toxicities. The first step to access these benefits is adherence to therapy.

Methods: This pilot study included eight pts (pts): four w/ breast cancer (BC) receiving neoadjuvant chemotherapy (TCHP), surgery, and radiotherapy, and four w/ anal cancer (AC) undergoing definitive chemoradiotherapy. Pts received an immunomodulatory supplement and a whey protein module throughout treatment, with dosage adjusted by treatment phase. The objective was to evaluate adherence to therapy, defined as >70% intake. Additionally, we evaluated treatment-related toxicities and nutritional parameters.

Results: Median age was 58 y (range 48-62). All pts were Subjective Global Assessment (SGA) A at baseline. Adherence was 50% in pts w/ BC and 75% in pts w/ AC. Pts w/ BC experienced BMI reduction (p=0.006), arm circumference decrease (p=0.009), and triceps skinfold increase (p=0.091) but maintained SGA grade A. No significant changes in parameters were observed in pts w/ AC, except for one case of SGA decline from grade A to B. Regarding treatment-related toxicities, no high-grade adverse events (AEs) were observed in pts with BC, while grade 3 nausea, vomiting, and radiodermatitis were each observed in one patient w/ AC.

Conclusion: Pts w/ AC demonstrated good adherence, while adherence in pts w/ BC was lower than desired. Proper adherence is essential to maximize nutritional therapy benefits so that larger studies can evaluate its impact in reducing treatment-related toxicities. Most pts maintained their nutritional status based on SGA.

Disclosure of Interest: None declared